Antiverse is an artificial intelligence (AI)-driven company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Murat Tunaboylu, Co-founder and CEO of Antiverse, speaks with Megan Thomas about how AI can advance therapeutic antibody design. Megan T: How is Antiverse using AI in cancer therapy? Murat T: Antiverse […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!